Related Experiment Video
Updated: Jun 12, 2026

05:28
Evaluation of a Reliable Biomarker in a Cecal Ligation and Puncture-Induced Mouse Model of Sepsis
Published on: December 9, 2022
[Establishment and evaluation of experimental sepsis mouse model]
Li-Yan Wang1, Ruo-Nan Xu, Gen-Cheng Han
1Department of Molecular Immunology, Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
|June 22, 2010
Summary
This study successfully created a mouse model for sepsis, a severe infection common in patients with blood cancers. This model mimics human sepsis symptoms, aiding future research into causes and treatments.
Area of Science:
- Hematology
- Immunology
- Infectious Diseases
Context:
- Malignant hematological diseases (leukemia, lymphoma, aplastic anemia) often lead to severe infections like sepsis.
- Sepsis is difficult to diagnose and has a high mortality rate, particularly in immunocompromised patients.
- Current understanding of sepsis pathogenesis in the context of hematological malignancies requires further in vivo investigation.
Purpose:
- To establish a reliable experimental mouse model for sepsis.
- To mimic the clinical presentation and pathological features of sepsis in a controlled setting.
- To provide a foundation for studying sepsis pathogenesis and developing therapeutic interventions in relevant disease contexts.
Summary:
- A caecal ligation and puncture (CLP) method was employed to induce sepsis in mice.
- Mice subjected to CLP exhibited high mortality, significant weight loss, and elevated inflammatory mediators (C5a, IL-6, TNF-alpha, IFN-gamma).
- CLP induced lymphocyte apoptosis in the thymus and mesenteric lymph nodes, alongside pathological damage to the thymus and spleen.
Impact:
- The established mouse model accurately replicates clinical sepsis symptoms and pathological changes.
- This model serves as a valuable tool for in vivo research into the mechanisms and treatment of sepsis.
- Facilitates the exploration of sepsis interventions in conjunction with malignant hematological diseases.

